In 2018, Oxervate was approved as an orphan drug to treat NK. An orphan drug is a drug that treats, prevents, or diagnoses a disease that affects fewer than 200,000 people in the U.S.
Oxervate is manufactured and distributed by the Italian company Dompẻ. Dompẻ’s American headquarters is in Boston, Massachusetts.
According to the National Library of Medicine, neurotrophic keratitis is a “degenerative corneal disease characterized by decreased or absent corneal sensation. The condition can lead to epithelial breakdown, impairment of healing, and ultimately corneal ulceration, melting, and perforation.” In more simple terms, an individual can’t feel their eye or has reduced sensation. Because of this, they may forget to blink or won’t notice their eye feels dry. This can lead to a breakdown of the cornea. When complications arise from this lost sensation, people with NK develop damage to their eye, leading to potential vision loss and blindness.
The Department of Ophthalmology, Massachusetts Eye and Ear Institute, Harvard Medical School, reported that an unusual white, thick, adherent corneal superficial plaque formation was reported after applying Oxervate. In addition to this, according to the New Drug Application (NDA), of the 151 patients in the trial, three patients on the drug had corneal deposits, while there were zero instances in the control group.
A recent journal article reported an analysis of the FDA reporting system database demonstrated cenergermin-related ocular adverse event signals. Those authors cautioned doctors to closely monitor patients to manage adverse reactions that may cause the occurrence of serious irreversible consequences following the use of the drug.
Questions About an Oxervate Lawsuit? Contact a Johnson//Becker Lawyer for a Free Case Review
If you or a loved one has complications after using Oxervate, you may want to speak with the lawyers at Johnson//Becker. We are currently accepting Oxervate lawsuits for those harmed by Oxervate across the country, and you may be entitled to financial compensation.
We offer a Free Case Evaluation. Please use the form below to contact us or call (800) 279-6386. We would be honored to speak with you and respond promptly to every inquiry we receive.
Free Case Evaluation
To contact us for a free review of your potential case, please fill out the form below or call us toll free 24 hrs/day by dialing: (800) 279-6386.